Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel

CV787, a PSA+ prostate cell-specific adenovirus variant, is currently in Phase I/II clinical trials for the treatment of prostate cancer. We have previously demonstrated that a single administration of CV787 at 1 x 10(11) particle/animal could eliminate established tumors within 6 weeks in nude mous...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2001-01, Vol.61 (2), p.517-525
Hauptverfasser:	YU, De-Chao, YU CHEN, DILLEY, Jeanette, YUANHAO LI, EMBRY, Millicent, HONG ZHANG, NGUYEN, Natalie, AMIN, Pinky, OH, Joe, HENDERSON, Daniel R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae - drug effects Adenoviridae - genetics Adenoviridae - growth & development Animals Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cell Line Cell Survival Chemotherapy DNA, Viral - administration & dosage Dose-Response Relationship, Drug Drug Synergism Humans Immunoblotting Male Medical sciences Mice Mice, Inbred BALB C Mice, Nude Neoplasm Transplantation Paclitaxel - administration & dosage Paclitaxel - analogs & derivatives Pharmacology. Drug treatments Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Taxoids Time Factors Treatment Outcome Tumor Cells, Cultured Tumor Suppressor Protein p53 - metabolism Virus Replication - drug effects Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!